Option and Collaboration Agreement Sample Contracts
OPTION AND COLLABORATION AGREEMENT between DENALI THERAPEUTICS INC. and TAKEDA PHARMACEUTICAL COMPANY LIMITEDOption and Collaboration Agreement • July 13th, 2018 • Denali Therapeutics Inc. • Biological products, (no disgnostic substances)
This Option and Collaboration Agreement (the “Agreement”) is made and entered into effective as of January 3, 2018 (the “Execution Date”) by and between Denali Therapeutics, Inc., a Delaware corporation (“Denali”), and Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan (“Takeda”). Denali and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
OPTION AND COLLABORATION AGREEMENTOption and Collaboration Agreement • February 3rd, 2016 • Cancer Prevention Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Option and Collaboration Agreement (“Agreement”) dated 9th day of January, 2016 (“Effective Date”) by and between Cancer Prevention Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, having a place of business at 1760 East River Road, Suite 250, Tucson, Arizona 85718 (“CPP”), and Sucampo AG, a corporation organized and existing under the laws of Switzerland, having a place of business at Baarerstrasse 22, 6300 Zug, Switzerland (“Sucampo”). CPP and Sucampo are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
Re: Option and Collaboration Agreement between Denali Therapeutics Inc. and Takeda Pharmaceutical Company Limited dated January 3, 2018 (the “Agreement”), as supplemented by that certain side letter to the Agreement pertaining to [***] dated September...Option and Collaboration Agreement • May 6th, 2025 • Denali Therapeutics Inc. • Biological products, (no disgnostic substances)
This letter will constitute notice that the [***] Collaboration Program is hereby terminated by Takeda pursuant to the provisions set forth in Section 14.3 of the Agreement, effective sixty (60) days from the date of this notice (or earlier if mutually agreed by the parties). This decision was taken after discussion with the JSC earlier this month, and it is our understanding that the JSC is aligned with and understands the rationale. Please be assured that Takeda will continue to comply fully with all applicable obligations under the Agreement and the Side Letter with respect to the termination and wind-down process for this Program.
OPTION AND COLLABORATION AGREEMENTOption and Collaboration Agreement • April 4th, 2022 • Social Capital Suvretta Holdings Corp. I • Surgical & medical instruments & apparatus • New York
This OPTION AND COLLABORATION AGREEMENT (this “Agreement”), dated as of December 19, 2018 (the “Effective Date”), is entered into by and between Akili Interactive Labs, Inc., a Delaware corporation having its principal place of business at 125 Broad Street, 4th Floor, Boston, MA 02110, U.S.A., (“Akili”), and Shionogi & Co., Ltd., a company organized under the laws of Japan having its principal place of business at 1 -8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045, Japan (“Shionogi”). Akili and Shionogi are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
OPTION AND COLLABORATION AGREEMENTOption and Collaboration Agreement • May 5th, 2016 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Option and Collaboration Agreement (“Agreement”) dated 9th day of January, 2016 (“Effective Date”) by and between Cancer Prevention Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, having a place of business at 1760 East River Road, Suite 250, Tucson, Arizona 85718 (“CPP”), and Sucampo AG, a corporation organized and existing under the laws of Switzerland, having a place of business at Baarerstrasse 22, 6300 Zug, Switzerland (“Sucampo”). CPP and Sucampo are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”